Scope and Claim Coverage for U.S. Patent 10,093,663 (Complement Alternative Pathway-Mediated Diseases) and the US Patent Landscape
U.S. Patent 10,093,663 claims broad US method-of-treatment coverage for administering a large genus of small-molecule compounds (Formula (I) and dependent embodiments) to treat complement alternative pathway (CAP) mediated disorders, with dependent claims narrowing to specific parameter bands and a large enumerated list of compound structures. The claim set is structurally geared to “genus-to-method” coverage: it ties disease indication scope (age-related macular degeneration, diabetic retinopathy, rheumatoid arthritis, SLE and SLE nephritis, asthma, glomerulonephritis) to the administration of compounds defined by a substituent-rich heteroaromatic/piperidine/indole scaffold family.
What is U.S. Patent 10,093,663 and what does it claim?
Core subject matter: A method of treating CAP-activated disorders by administering a therapeutically effective amount of a compound, salt, or tautomer having the Formula (I) scaffold described in the claims.
Claim 1: What conditions are covered and how broad is the method-of-use?
Claim 1 disease set (closed list):
- age-related macular degeneration (AMD)
- diabetic retinopathy
- rheumatoid arthritis
- systemic lupus erythematosus (SLE)
- SLE nephritis
- asthma
- glomerulonephritis
Mechanistic framing: The diseases are “mediated by activation of the complement alternative pathway.” That limitation is the primary linkage between the method and the CAP therapeutic rationale.
Treatment modality: Administration of “a therapeutically effective amount” of a compound of Formula (I), including:
Claim 1: What chemical coverage does Formula (I) provide?
Formula (I) is defined by a large number of substitution variables. In practice, Claim 1 covers a genus spanning:
- variable ring saturation and spirocyclic embodiments (via W and R6)
- variable indole/heteroaryl substitution patterns
- multiple pendant substituent classes (sulfonamides, carboxylic acids, tetrazoles, sulfonyl analogs, heteroaryl fragments)
Key variable bands explicitly recited in Claim 1:
- n = 0, 1, or 2
- R = hydrogen, C1–C4alkyl, or hydroxyC1–C4alkyl
- R1 includes halogen and extensive functional groups (hydroxy; C1–C6alkyl; alkenyl; cycloalkyl; alkoxy; haloalkyl/haloalkoxy; sulfonate-like “—S(O)pC1–C6alkyl”; urea-like “—CH2NHC(O)C1–C4alkyl”; and “—OCH2C(O)R7”)
- p = 0, 1, or 2
- R2 = C1–C6alkyl / C1–C6alkoxy / hydroxyC1–C6alkyl / halogen
- R3 = hydrogen, halogen, cyano, C1–C4alkyl, haloC1–C4alkyl, “—CH2C(O)R7”, phenyl, or a 5/6-member heteroaryl with 1–3 N/O/S atoms, optionally substituted by 0–2 C1–C4alkyl
- R4 = phenyl/naphthyl/5–6-member heteroaryl with 1–3 N/O/S, optionally substituted with R5 plus 0–1 additional substituents chosen from halogen, C1–C4alkyl, C1–C4alkoxy, hydroxyl, and cyanomethyl
- R5 includes: “—C(O)R8”, “—CH2C(O)R8”, “R9”, amide/sulfonamide motifs including “—C(O)NHSO2C1–C4alkyl”, “—SO2NHC(O)C1–C4alkyl”, “—SO2N(H)m(C1–C4alkyl)2–m”, “—SO2C1–C4alkyl”, cyano, halogen, hydroxylC1–C4alkyl, and 5-member heteroaryl fragments with ring N and optional S/O
- m = 0, 1, or 2
- W = O or C(R6)2
- R6 includes wide range of substituents including amines and hydroxyalkyl and permits “in combination, form a spirocyclic carbocycle having 3 to 6 ring atoms”
- R7 = hydroxy, C1–C4alkoxy, amino, or substituted amines
- R8 = hydroxy, C1–C4alkoxy, amino, or 5–7-member saturated heterocycle with N/O/S, or dialkylamino substituted with halogen/hydroxy/alkyl
- R9 = 5-member heteroaryl with 1–4 ring N and optional O/S, optionally substituted by 0–2 C1–C4alkyl
Functional consequence: Claim 1’s chemical definition is sufficiently broad to cover many analogs that maintain the same core scaffold architecture but vary:
- ring substituents (R, R1–R4)
- terminal acidic/amide/sulfonamide groups (R5 and R8/R9 classes)
- saturation/bridging/spiro features (W and R6)
Claim 2–14: What specific refinements narrow Claim 1?
Dependent claims (2–14) carve out sub-portions of the Formula (I) genus.
Examples of dependent claim narrowing:
- Claim 2: n = 1
- Claim 3: W = CHR6 or C(CH3)R6
- Claim 4: R1 = C1–C4alkyl, C1–C4alkoxy, or cyclopropyl
- Claim 5: R2 = methyl
- Claim 6–7: R3 = hydrogen (Claim 7 restates a narrower subset) or hydrogen/halogen/alkyl (Claim 6)
- Claims 8 and 13: specific embodiments “according to Formula (IIa)/(IIb)” and “according to Formula (IVa)/(IVb)” (exact structural moieties are referenced but not reproduced in the prompt)
- Claim 9: embodiments “according to Formula (IIIa)/(IIIb)” with X = N or CH
- Claims 10–12: R4 = pyridin-3-yl or phenyl para-substituted to the piperidine ring with R5, plus optional substituent set (fluoro/methoxy/hydroxymethyl/hydroxy)
- Claim 14: R5 = CO2H, CO2NH2, SO2NH2, or tetrazolyl
Claim 15–16: What specific compounds are enumerated?
Claim 15 enumerates a very large explicit list of compound embodiments consistent with the Formula (I) framework and related stereochemistry/salts/tautomers. This is the practical “anchor” that demonstrates that the patentee has support and target structures within the broader genus.
Claim 16 narrows to a specific compound:
- 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid) or a pharmaceutically acceptable salt.
Claims 17–18: How does the indication scope narrow?
- Claim 17: glomerulonephritis
- Claim 18: age-related macular degeneration
Net scope result: broad method-of-treatment coverage across multiple CAP-mediated diseases, with additional claims that narrow to individual indications.
How strong is the patent estate for complement alternative pathway CAP-mediated treatments under U.S. Patent 10,093,663?
Based only on the claim text provided, the enforceable “strength” depends on two structural pillars:
-
A defined chemical genus with many degrees of freedom.
The genus language in Claim 1 is expansive, making it harder for generics or competitors to design around using minor substituent changes, unless they fall outside one of the many parameter constraints.
-
A defined mechanistic disease limitation.
The method is limited to diseases “mediated by activation of the complement alternative pathway.” Competitors often try to avoid direct infringement by changing:
- the asserted indication
- the mechanistic disease characterization in label/regulatory strategy
- the compound class (design-around)
Critical observation: The claim language ties CAP mediation to the disease list, but the prompt provides no additional claim language about:
- biomarker confirmation
- patient selection thresholds
- assays proving CAP activation
If the specification supports broad CAP mediation, Claim 1 can reach broad populations so long as the clinical rationale ties to CAP.
What do claims suggest about the therapeutic target class and mechanism?
The claims do not name a specific complement protein or receptor in the excerpt. The claims do tie to CAP activation generally, which typically corresponds to therapies targeting:
- complement component proteins upstream of or within the alternative pathway
- regulators that modulate CAP activation cascades
The chemical scaffold is clearly a proprietary small-molecule series with indole-piperidine architecture plus variable sulfonamide/carboxylic acid/tetrazole groups, implying:
- target engagement by a small-molecule binding event rather than antibody-mediated pathways
That said, the excerpt is limited to the method-of-treatment definition; target identity is not stated.
How many patent claims cover the same scaffold vs. specific embodiments?
From the provided claim set:
- Claim 1: genus method claim across all listed CAP-mediated diseases.
- Claim 2–14: about 12 dependent claim refinements (each selects subsets of the genus parameters and specific structural families via referenced Formulas II–IV and substituent constraints).
- Claim 15: explicit compound list (multiple named molecules).
- Claim 16: one specific stereoisomeric acid (2S,4S).
- Claims 17–18: indication-specific method claims.
Practical partitioning:
- Chemical scope is protected both as a genus (Claim 1) and as an enumerated set (Claim 15) plus specific marker embodiments (Claim 16).
- Indication scope is protected as a set of diseases (Claim 1) and as two narrower indication-specific claims (Claims 17 and 18).
What patent landscape risks exist for generic or biosimilar entry?
A generic “biosimilar” framing likely does not apply because the claims are for small molecules (not biologics). The main entry risk is generic small-molecule infringement under:
- literal method-of-use infringement (if a product is used for the claimed CAP-mediated diseases with the claimed compounds)
- contributory inducement or induced infringement theories (if a product is marketed for those indications and the active is within the claim genus)
Design-around approach: A competitor could attempt to avoid infringement by:
- switching to a different chemical scaffold that falls outside at least one of the parameter constraints in Formula (I)
- pursuing clinical use that is not “mediated by CAP activation” as framed in the infringement theory
- using compounds/salts/tautomers that fall outside the enumerated genus boundaries
However, Claim 15’s extensive enumerated set reduces the practical value of relying on “minor differences” if those differences still map into the Formula (I) parameter space.
Which formulations or salt forms are protected by U.S. Patent 10,093,663?
The prompt indicates that the method claims cover:
- the compound
- “of salt or tautomer thereof”
The claims do not list specific pharmaceutical compositions, dosages, or excipients. Coverage is method-of-use, not formulation composition per se.
Salt/tautomer coverage implication: Competitors can sometimes argue that a different salt form is outside patent language, but here salts and tautomers are explicitly included. The best design-around is therefore more likely to be chemical structural, not salt selection.
What specific structure features appear most central to claim scope?
Across Claim 1 and the enumerated Claim 15 list, the repeated structural themes include:
- indole core substituted at positions consistent with “5,7-dimethyl-1H-indole” and related indole substitution bands (e.g., methoxy/methyl/cyclopropyl variants)
- a piperidine ring with substituents at 2 and 4 positions (including carbinol and amide/sulfonamide-bearing groups)
- a connecting “(…)methyl” bridge linking indole and piperidine
- a phenyl or heteroaryl group (often para-relationship to the piperidine ring) bearing acidic or amide/sulfonamide functionalities:
- carboxylic acids (benzoic acids and substituted benzoates)
- benzamides
- sulfonamides
- tetrazole-containing aryl groups
Those recurring motifs likely define the “novelty backbone” of the patent family.
What patent litigation affects U.S. Patent 10,093,663?
No litigation docket data is included in the prompt. Without a provided case list, there is no basis to map enforcement actions, Markman rulings, settlement terms, or PTAB challenges to this specific patent.
What is the Orange Book status of U.S. Patent 10,093,663?
No Orange Book entries, FDA product codes, or listed NDA/BLA numbers are provided in the prompt. Without those identifiers, an Orange Book status mapping cannot be produced from the claim excerpt alone.
Commercial relevance: Which drug products could this patent cover?
The prompt provides a set of enumerated example compounds, but it does not provide:
- proprietary drug name
- INN/USAN
- NDA/BLA identifiers
- labeling indication claims
Without those external identifiers, it is not possible to connect the compound list to specific marketed products or pipeline candidates in the US.
Key Takeaways
- Claim 1 is a broad method-of-treatment patent covering multiple CAP-mediated diseases through administration of compounds defined by a substitution-rich Formula (I) genus.
- Dependent claims (2–14) narrow specific variable bands (n, W, R1–R3 constraints, R4 phenyl/pyridinyl patterns, and R5 functional group classes including carboxylic acids and tetrazoles).
- Claims 15–16 provide strong support coverage via an extensive enumerated list of specific compound structures and a direct claim to one stereochemically defined benzoic acid.
- Claims 17–18 add indication-specific method claims for glomerulonephritis and age-related macular degeneration.
- Practical design-around is likely chemical (outside Formula (I) parameter space) rather than salt/formulation selection because salts and tautomers are expressly included.
FAQs
- Does Claim 1 require proof that a patient has CAP activation, or is it sufficient that the disease is known to involve CAP?
- Can a competitor avoid infringement by changing only the salt or tautomer form of the active compound?
- Which claim variables most constrain design-around: R1/R2/R3 substituents, R4 aryl selection, or R5 acidic/amide functionality?
- If a competitor markets for an indication not listed in Claim 1, could inducement theories still create infringement risk?
- How do Claims 15–16 affect freedom-to-operate compared with relying on purely genus-based design-around?
References
- U.S. Patent 10,093,663, claims (provided in prompt).
